Legend Biotech (LEGN) drew fresh attention after reporting first quarter 2026 results, with revenue of US$305.1 million, a narrower net loss of US$54.3 million, and reduced loss per share versus a year earlier.

The quarterly update comes after a sharp 54.47% 90 day share price return and a 30.13% year to date share price gain, contrasting with a 3.65% decline in 1 year total shareholder return and a 55.77% decline over 3 years. This suggests recent momentum has picked up following a tougher longer term experience for shareholders.

If Legend Biotech's cell therapy story has caught your eye, it can be worth comparing it with other healthcare companies using AI. You can start with 33 healthcare AI stocks

With Legend Biotech still loss making but reporting quarterly revenue of US$305.1 million and a sharp 90 day share price jump, you have to ask: is there real value left here, or is the market already pricing in future growth?

Most Popular Narrative: 51.1% Undervalued

At a last close of $27.99 versus a narrative fair value estimate of $57.24, the widely followed story around Legend Biotech leans heavily toward upside potential, anchored to how the multiple myeloma opportunity is modeled.

Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by strong survival data, ongoing clinical trials (CARTITUDE-5 and CARTITUDE-6), and label updates that increase patient access, setting up long-term revenue acceleration as the patient pool widens.

Want to see what revenue ramp, margin shift, and profit trajectory are baked into that fair value? The narrative leans on aggressive growth, rising profitability, and a richer future earnings multiple. Curious which assumptions matter most and how they connect back to today’s price?

Result: Fair Value of $57.24 (UNDERVALUED)

However, the story can change quickly if CARVYKTI underperforms expectations or if competitors gain more share, which would challenge the upside implied in the current narrative.

Another View Using Sales Multiples

The fair value story points to upside, but the P/S ratio tells a more mixed tale. At 4.6x, Legend Biotech trades well below the US Biotechs average of 10.4x, yet above the fair ratio of 3.4x that the market could move toward as expectations reset. Is that gap a cushion or a warning sign?

Next Steps

With sentiment leaning toward upside and clear rewards on the table, it helps to move quickly and test the story against the numbers yourself. To see what the market is optimistic about right now, take a closer look at the 1 key reward.

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that fit your goals even better, so consider broadening your radar with a few targeted screens.

• Spot potential bargains early by scanning screener containing 20 high quality undiscovered gems that combine quality fundamentals with limited market attention.
• Strengthen your portfolio foundation by focusing on companies in the solid balance sheet and fundamentals stocks screener (46 results) that prioritize financial resilience.
• Dial down volatility by checking out 66 resilient stocks with low risk scores designed to highlight stocks with more stable risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.